![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety Profile of Cabotegravir + Rilpivirine During Oral Lead-In and Through Long-Acting Therapy: Pooled Analysis of the Phase 3 FLAIR, ATLAS, and ATLAS-2M Studies
|
|
|
EACS 2021 Oct 27-30
Patricia de los Rios1, Parul Patel1, Jenny Huang2, Conn Harrington1, Ronald D'Amico1, Shanker Thiagarajah3, Eileen Birmingham4, Rodica Van Solingen-Ristea5, William R. Spreen1, Bryan Baugh6, Matt Bosse7
1ViiV Healthcare, Research Triangle Park, NC, United States; 2GlaxoSmithKline, Mississauga, Ontario, Canada; 3GlaxoSmithKline, London, United Kingdom; 4Janssen Research & Development LLC, Raritan, NJ, United States;
5Janssen Research & Development, Beerse, Belgium; 6Janssen Pharmaceutical, Research & Development, Titusville, NJ, United States; 7ViiV Healthcare, San Diego, CA, United States
![1101211](../images/110121/110121-13/1101211.gif)
![1101212](../images/110121/110121-13/1101212.gif)
![1101213](../images/110121/110121-13/1101213.gif)
![1101214](../images/110121/110121-13/1101214.gif)
![1101215](../images/110121/110121-13/1101215.gif)
![1101216](../images/110121/110121-13/1101216.gif)
![1101217](../images/110121/110121-13/1101217.gif)
![1101218](../images/110121/110121-13/1101218.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|